NASH Core Curriculum: Imaging and Laboratory Tests for Diagnosis and Risk Stratification

Learn the best tools and approaches to identify NAFLD and to rule in or rule out NASH fibrosis.
Wing-Kin Syn, MBChB, PhD, FACP, FRCP
Format: Microsoft PowerPoint (.ppt)
File Size: 1.57 MB
Released: April 27, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Supported by educational grants from
Gilead Sciences
Novo Nordisk Inc.

Related Content

Unlocked slides from Giada Sebastiani, MD and CCO: Role of diet, exercise, and current treatments for NASH

person default Giada Sebastiani, MD Released: June 2, 2021

Expert advice on current NAFLD/NASH treatments: Mediterranean diet, vitamin E, pioglitazone, GLP-RAs, eg semaglutide. From Clinical Care Options (CCO)

person default Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: June 1, 2022

Video from CCO: best practice for identifying NAFLD and risk of progression to NASH. Biomarkers and imaging to rule in or out significant/advanced hepatic fibrosis

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 27, 2021 Expired: April 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue